Aldeyra Therapeutics up as drug reduces cough in mid-stage trial
27/06/2023 13:41
** Shares of biotechnology company Aldeyra Therapeutics
ALDX.O up 3.86% at $7.80 premarket
** Co announces "statistically significant" reduction in
cough frequency in mid-stage clinical trial of orally
administered ADX-629 in patients with chronic cough urn:newsml:reuters.com:*:nBw4YppMsa
** Co says ADX-629 was well tolerated and no safety concerns
were identified
** Mid-stage clinical trial of ADX-629 in moderate
alcohol-associated hepatitis is expected to initiate in the
second half of 2023
** As of Monday's close, ALDX was up ~8% YTD
(Reporting by Pritam Biswas in Bengaluru)
((Pritam.Biswas@thomsonreuters.com))
Recent news on Aldeyra Therapeutics
See all newsBrief: Aldeyra Therapeutics Pays Off $15 Million Outstanding Borrowings, Terminates Hercules Credit Facility - SEC Filing
U.S. STOCKS ON THE MOVE -Steel Dynamics, Aldeyra, Cencora
U.S. STOCKS ON THE MOVE-Qualcomm, Canadian Solar, Draftkings
Aldeyra tumbles to record low after FDA declines to approve experimental dry eye drug
Aldeyra plunges after FDA declines to approve experimental dry eye drug